B 细胞在多发性硬化症免疫发病机制中的作用。
The role of B cells in the immunopathogenesis of multiple sclerosis.
机构信息
Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Department of Immunology, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
出版信息
Immunology. 2020 Aug;160(4):325-335. doi: 10.1111/imm.13198. Epub 2020 May 10.
Abstract
There is ongoing debate on how B cells contribute to the pathogenesis of multiple sclerosis (MS). The success of B-cell targeting therapies in MS highlighted the role of B cells, particularly the antibody-independent functions of these cells such as antigen presentation to T cells and modulation of the function of T cells and myeloid cells by secreting pathogenic and/or protective cytokines in the central nervous system. Here, we discuss the role of different antibody-dependent and antibody-independent functions of B cells in MS disease activity and progression proposing new therapeutic strategies for the optimization of B-cell targeting treatments.
摘要
目前，关于 B 细胞如何导致多发性硬化症（MS）的发病机制仍存在争议。B 细胞靶向治疗在 MS 中的成功凸显了 B 细胞的作用，特别是这些细胞的抗体非依赖性功能，例如将抗原呈递给 T 细胞，以及通过在中枢神经系统中分泌致病性和/或保护性细胞因子来调节 T 细胞和髓样细胞的功能。在这里，我们讨论了 B 细胞在 MS 疾病活动和进展中的不同抗体依赖性和抗体非依赖性功能的作用，并提出了优化 B 细胞靶向治疗的新治疗策略。
相似文献
1
The role of B cells in the immunopathogenesis of multiple sclerosis.
Immunology. 2020 Aug;160(4):325-335. doi: 10.1111/imm.13198. Epub 2020 May 10.
2
Reassessing B cell contributions in multiple sclerosis.
Nat Immunol. 2018 Jul;19(7):696-707. doi: 10.1038/s41590-018-0135-x. Epub 2018 Jun 20.
3
The Multiple Roles of B Cells in Multiple Sclerosis and Their Implications in Multiple Sclerosis Therapies.
Cold Spring Harb Perspect Med. 2019 Apr 1;9(4):a029108. doi: 10.1101/cshperspect.a029108.
4
Further understanding of the immunopathology of multiple sclerosis: impact on future treatments.
Expert Rev Clin Immunol. 2016 Oct;12(10):1069-89. doi: 10.1080/1744666X.2016.1191351. Epub 2016 Jun 23.
5
Memory B Cells in Multiple Sclerosis: Emerging Players in Disease Pathogenesis.
Front Immunol. 2021 Jun 8;12:676686. doi: 10.3389/fimmu.2021.676686. eCollection 2021.
6
The role of B cells in multiple sclerosis: rationale for B-cell-targeted therapies.
Curr Opin Neurol. 2008 Apr;21 Suppl 1:S9-S18. doi: 10.1097/01.wco.0000313359.61176.15.
7
B and T Cells Driving Multiple Sclerosis: Identity, Mechanisms and Potential Triggers.
Front Immunol. 2020 May 8;11:760. doi: 10.3389/fimmu.2020.00760. eCollection 2020.
8
B cells and multiple sclerosis.
Lancet Neurol. 2008 Sep;7(9):852-8. doi: 10.1016/S1474-4422(08)70192-3.
9
Multiple Sclerosis: New Aspects of Immunopathogenesis.
Acta Clin Croat. 2018 Jun;57(2):352-361. doi: 10.20471/acc.2018.57.02.17.
10
Cooperation of B cells and T cells in the pathogenesis of multiple sclerosis.
Results Probl Cell Differ. 2010;51:115-26. doi: 10.1007/400_2009_21.
引用本文的文献
1
NETosis in hypersensitivity disorders.
Mol Biol Rep. 2025 Jun 9;52(1):574. doi: 10.1007/s11033-025-10629-6.
2
Overtime Challenges of Diagnosis and Treatment in Two Pediatric Patients with Extensive Cerebral Tumefactive Lesions Indicative of Baló's Type Multiple Sclerosis.
Children (Basel). 2025 May 14;12(5):630. doi: 10.3390/children12050630.
3
Lycopene Supplemented Mediterranean Diet Ameliorates Experimental Autoimmune Encephalomyelitis (EAE) in Mice and Changes Intestinal Microbiome.
J Neuroimmune Pharmacol. 2025 May 5;20(1):50. doi: 10.1007/s11481-025-10212-7.
4
[Multiple sclerosis and the Epstein-Barr Virus: Current perspectives on their pathogenic mechanisms].
Rev Med Inst Mex Seguro Soc. 2025 Mar 3;63(2):e6391. doi: 10.5281/zenodo.14617124.
5
Alterations in neutrophil mRNA profiles in multiple sclerosis and identification of candidate genes for further investigation.
Front Neurol. 2025 Feb 17;16:1548196. doi: 10.3389/fneur.2025.1548196. eCollection 2025.
6
Pathway analysis of peripheral blood CD8+ T cell transcriptome shows differential regulation of sphingolipid signaling in multiple sclerosis and glioblastoma.
PLoS One. 2024 Jun 11;19(6):e0305042. doi: 10.1371/journal.pone.0305042. eCollection 2024.
7
Revolutionizing Neurological Disorder Treatment: Integrating Innovations in Pharmaceutical Interventions and Advanced Therapeutic Technologies.
Curr Pharm Des. 2024;30(19):1459-1471. doi: 10.2174/0113816128284824240328071911.
8
EBNA1 Inhibitors Block Proliferation of Spontaneous Lymphoblastoid Cell Lines From Patients With Multiple Sclerosis and Healthy Controls.
Neurol Neuroimmunol Neuroinflamm. 2023 Aug 10;10(5). doi: 10.1212/NXI.0000000000200149. Print 2023 Sep.
9
Safety and efficacy of cladribine in multiple sclerosis: a systematic review and meta-analysis.
Neurol Sci. 2023 Sep;44(9):3045-3057. doi: 10.1007/s10072-023-06794-w. Epub 2023 Apr 17.
10
Recent Progress in Multiple Sclerosis Treatment Using Immune Cells as Targets.
Pharmaceutics. 2023 Feb 22;15(3):728. doi: 10.3390/pharmaceutics15030728.
本文引用的文献
1
IL-21 and IL-21-producing T cells are involved in multiple sclerosis severity and progression.
Immunol Lett. 2019 Dec;216:12-20. doi: 10.1016/j.imlet.2019.09.003. Epub 2019 Sep 20.
2
The role of immune regulatory molecules in multiple sclerosis.
J Neuroimmunol. 2019 Dec 15;337:577061. doi: 10.1016/j.jneuroim.2019.577061. Epub 2019 Sep 5.
3
Myeloid-derived suppressor cells control B cell accumulation in the central nervous system during autoimmunity.
Nat Immunol. 2018 Dec;19(12):1341-1351. doi: 10.1038/s41590-018-0237-5. Epub 2018 Oct 29.
4
Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study.
Neurology. 2018 May 15;90(20):e1805-e1814. doi: 10.1212/WNL.0000000000005516. Epub 2018 Apr 25.
5
Multiple Sclerosis Pathology.
Cold Spring Harb Perspect Med. 2018 Mar 1;8(3):a028936. doi: 10.1101/cshperspect.a028936.
6
Clinical Course of Multiple Sclerosis.
Cold Spring Harb Perspect Med. 2018 Sep 4;8(9):a028928. doi: 10.1101/cshperspect.a028928.
7
Effector T Cells in Multiple Sclerosis.
Cold Spring Harb Perspect Med. 2018 Apr 2;8(4):a029025. doi: 10.1101/cshperspect.a029025.
8
Regulatory T Cells: From Discovery to Autoimmunity.
Cold Spring Harb Perspect Med. 2018 Dec 3;8(12):a029041. doi: 10.1101/cshperspect.a029041.
9
Teriflunomide treatment reduces B cells in patients with MS.
Neurol Neuroimmunol Neuroinflamm. 2017 Oct 23;4(6):e403. doi: 10.1212/NXI.0000000000000403. eCollection 2017 Nov.
10
Fingolimod induces BAFF and expands circulating transitional B cells without activating memory B cells and plasma cells in multiple sclerosis.
Clin Immunol. 2018 Feb;187:95-101. doi: 10.1016/j.clim.2017.10.009. Epub 2017 Oct 25.
Zotero 插件